T0	Outcomes 56 155	accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction
T1	Outcomes 208 230	accelerated lipolysis.
T2	Outcomes 305 328	lipolytic effect of GH.
T3	Outcomes 497 543	increasing insulin-like growth factor (IGF)-I.
T4	Outcomes 615 720	lipolytic and anabolic actions, as well as the consequent changes in insulin and GH secretion in obesity.
T5	Outcomes 1089 1164	fraction of body weight lost as fat and a greater loss of visceral fat area
T6	Outcomes 1258 1272	lean body mass
T7	Outcomes 1299 1324	negative nitrogen balance
T8	Outcomes 1388 1402	lean body mass
T9	Outcomes 1432 1457	positive nitrogen balance
T10	Outcomes 1513 1530	increase in IGF-I
T11	Outcomes 1561 1594	GH response to L-dopa stimulation
T12	Outcomes 1599 1606	blunted
T13	Outcomes 1726 1740	insulin levels
T14	Outcomes 1814 1842	free fatty acid (FFA) levels
T15	Outcomes 1872 1880	FFA area
T16	Outcomes 1940 1958	visceral fat loss.
T17	Outcomes 2047 2112	body fat loss, exerts anabolic effects and improves GH secretion.